Please login to the form below

Not currently logged in
Email:
Password:

Juno Therapeutics names Cindy Elkins as CIO

She joins the biopharma from Genentech, where she was VP of IT

Cindy Elkins has joined Juno Therapeutics - now a part of Celgene - as its new chief information officer, a role that will see her report directly to Hans Bishop, Juno’s president and chief executive officer.

He said: “Cindy is a leader with a track record of increasing the impact of information technology in the biotech industry, focusing on innovation and delivering advanced technologies that support the discovery of breakthrough therapies.

“Her talent, passion and experience will help us advance our mission to bring better medicines to patients.”

Elkins most recently served as vice president, IT for the Americas at Genentech, where she led its US commercial technology integration following the firm's acquisition by Roche.

She said: “I am delighted to join Juno, a company that reflects my passion for vibrant, accountable, high-performing organisations seeking to transform and innovate at scale.

“It is an honour to be a part of a mission to fundamentally change the way cancer and other diseases are treated, and to provide the tools and infrastructure to allow Juno’s employees to do their best work.”

7th February 2018

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics